Table 4 Secondary analysis: cSMS and RCSS of AIT with DPAEs compared with placebo (all study seasons)
Study subgroups | GINA + ARIA score | Study subgroups | Efficacy evaluation period | cSMS as primary | All cSMS | All RCSS |
|---|---|---|---|---|---|---|
Intermittent asthma Any rhinoconjunctivitis severity | 0 | Pfaar, 2010 (Pollen) | 24 mo. (Primary) | 0.4 (0.1 to 0.7) | 0.4 (0.1 to 0.7) | 0.4 (0.1 to 0.7) |
Intermittent to mild asthma Moderate to severe rhinoconjunctivitis | 1 | Pfaar, 2012 (Pollen) | 24 mo. (Primary) 12 mo. (Secondary) | 1.1 (0.9 to 1.3) | 1.1 (0.9 to 1.2) | 1.3 (0.7 to 1.9) |
Pfaar, 2013 (Pollen) | 24 mo. (Primary) 12 mo. (Secondary) | |||||
Colás, 2006 (Pollen) | 12 mo. (Primary) | |||||
Höiby, 2010 (Pollen) | 24 mo. (Primary) | |||||
Intermittent to moderate asthma or Moderate to severe rhinoconjunctivitis | 2 | Alvarez-Cuesta, 2005 (Pollen) | 12 mo. (Primary) | 2.6 (2.1 to 3.1) | 2.6 (2.1 to 3.1) | 2.3 (1.8 to 2.8) |
Ameal, 2005 (HDM) | 12 mo. (Primary) | |||||
Intermittent to moderate asthma & Moderate to severe rhinoconjunctivitis | 3 | García-Robaina, 2006 (HDM) | 12 mo. (Primary) | 5.1 (3.9 to 6.2) | 5.1 (3.9 to 6.2) | 4.4 (3.4to 5.4) |